Fiduciary Alliance LLC acquired a new position in Baxter International Inc. (NYSE:BAX - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 63,202 shares of the medical instruments supplier's stock, valued at approximately $1,914,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new position in Baxter International in the 1st quarter valued at about $27,000. Rossby Financial LCC bought a new position in shares of Baxter International during the first quarter valued at approximately $29,000. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Baxter International by 48.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 2,021 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 656 shares in the last quarter. Archer Investment Corp lifted its position in shares of Baxter International by 20.5% in the first quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier's stock valued at $100,000 after acquiring an additional 500 shares in the last quarter. Finally, Bruce G. Allen Investments LLC lifted its stake in Baxter International by 35.2% in the first quarter. Bruce G. Allen Investments LLC now owns 3,546 shares of the medical instruments supplier's stock worth $121,000 after purchasing an additional 924 shares during the last quarter. Institutional investors and hedge funds own 90.19% of the company's stock.
Baxter International Stock Down 2.8%
Shares of BAX stock traded down $0.66 on Friday, reaching $23.03. 13,671,637 shares of the company's stock traded hands, compared to its average volume of 5,815,892. The company has a market capitalization of $11.83 billion, a P/E ratio of -76.77, a price-to-earnings-growth ratio of 0.75 and a beta of 0.61. The business's 50 day moving average price is $24.98 and its two-hundred day moving average price is $28.96. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.49 and a current ratio of 2.30. Baxter International Inc. has a 12-month low of $21.33 and a 12-month high of $39.57.
Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.01). Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The firm had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.82 billion. During the same period in the prior year, the firm posted $0.68 earnings per share. The business's revenue for the quarter was up 4.3% compared to the same quarter last year. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. On average, equities analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current year.
Baxter International Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Friday, August 29th will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 dividend on an annualized basis and a yield of 3.0%. Baxter International's dividend payout ratio is -226.67%.
Analyst Ratings Changes
BAX has been the topic of several analyst reports. Wells Fargo & Company reduced their price target on Baxter International from $33.00 to $24.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. Stifel Nicolaus reaffirmed a "hold" rating and set a $25.00 price objective (down previously from $36.00) on shares of Baxter International in a research note on Monday, August 4th. Citigroup lowered their target price on shares of Baxter International from $34.00 to $32.00 and set a "neutral" rating for the company in a research note on Wednesday, July 9th. Wall Street Zen lowered shares of Baxter International from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley lowered their price target on Baxter International from $28.00 to $27.00 and set an "underweight" rating for the company in a research note on Tuesday, July 15th. Three analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Baxter International has a consensus rating of "Hold" and a consensus price target of $30.11.
Get Our Latest Report on BAX
Baxter International Company Profile
(
Free Report)
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Featured Stories

Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.